Impulse News

Clinical Registry Data and recently published FIX-HF-5C were presented at the Late-Breaking Clinical Trial Session at EHF 2018

Stuttgart, Germany, May 28th, 2018 – Impulse Dynamics Germany, GmbH announced results on “Real World” experience from its European Clinical Registry. The results were presented today by Prof. Gerd Hasenfuß, MD, Professor of Internal Medicine and Director of the Heart Center, University Hospital Göttingen, Germany at the Late-Breaking Clinical Trials Session of the European Heart […]

Read more

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of Internal Medicine and Director, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, at the […]

Read more

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure.  The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou.  “This is a major milestone for Impulse Dynamics, as it will help […]

Read more

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.

Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac Contractility Modulation (CCM™) device. Impulse Dynamics proprietary CCM™ technology delivers non-excitatory electric pulses to the cardiac muscle with the […]

Read more

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM™) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round. The equity financing round was led by Goldstone Investment, a global investment company belonging to the Chinese conglomerate CITIC Securities, […]

Read more

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017 — Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM™) signals delivered by the implantable Optimizer® […]

Read more

Going red to raise awareness of heart disease in women

Mt. Laurel, New Jersey, February 3 2017 Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day. February has been known as American Heart Month since the early 1960s, but in 2003 National Wear Red Day was introduced specifically to […]

Read more

Impulse Dynamics Successfully Launches the Optimizer® Smart Device for Heart Failure Treatment in Europe

Impulse Dynamics has launched the next generation of its Optimizer® device, the Optimizer® Smart, in Europe after it received the CE mark. The Optimizer® Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy. The device is based on novel cardiac contractility […]

Read more

Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award

September 12, 2016 – Impulse Dynamics, developer of the Optimizer® IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the prestigious Frost & Sullivan 2016 European Chronic Heart Failure Therapy New Product Innovation Award. Based on a recent analysis of the European chronic heart failure therapy market, Frost & […]

Read more
Page 1 of 41234